NOVAVAX, INC. (NASDAQ:NVAX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
Fourth Quarter Financial Results
On March 11, 2020, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended December 31, 2019. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Items 2.02 and 9.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press release, dated March 11, 2020, regarding the Company’s financial results for the quarter ended December 31, 2019. |
NOVAVAX INC Exhibit
EX-99.1 2 tm2012527d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Novavax Reports Fourth Quarter and Full Year 2019 Financial Results ·NanoFlu top-line data from Phase 3 clinical trial expected by the end of this month ·Novavax awarded CEPI funding to support COVID-19 vaccine program ·COVID-19 Phase 1 clinical trial expected to initiate in late spring of 2020 ·Company to host conference call today at 4:30 p.m. ET Gaithersburg,…
To view the full exhibit click here
About NOVAVAX, INC. (NASDAQ:NVAX)
Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).